| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10911468 | Lung Cancer | 2012 | 8 Pages |
Abstract
Customized treatment with trabectedin 1.3Â mg/m2 3-h q3wk according to composite gene signature (XPG and/or ERCC1 overexpression, and BRCA1 underexpression) was well tolerated, but had modest activity in NSCLC patients pretreated with platinum. Therefore, further clinical trials with trabectedin as single agent in this indication are not warranted.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Bartomeu Massuti, Manuel Cobo, Carlos Camps, Manuel Dómine, Mariano Provencio, Vicente Alberola, Nuria Viñolas, Rafael Rosell, Miguel Tarón, Vanesa Gutiérrez-Calderón, Pilar Lardelli, Vicente Alfaro, Antonio Nieto, Dolores Isla,